Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery
Authors' conclusion
Among adults with post-MBS weight recurrence, GLP-1 RAs were associated with greater weight loss without increased adverse events.
Study context
- Population
- Adults with ≥ 10% weight recurrence after metabolic and bariatric surgery (MBS), OneFlorida+ Data Trust (2015–2024)
- Exposure
- GLP-1 RA users vs non-users
- Outcome
- Percentage of recurrent weight lost [(index weight - follow-up weight) ÷ (index weight - nadir weight) × 100]
- Follow-up
- 6 and 12 months
Methodological detailsnew-user design, matched on BMI and timing of clinical encounter, inverse probability of treatment weighting
- New-user design
- Matched on BMI and timing of clinical encounter
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Percentage of recurrent weight lost · 6 months
P = 0.005
Observational data: associations, not effects.
Further findings
Percentage of recurrent weight lost · 12 months
P = 0.017
- Percentage of recurrent weight lost: 72 users and 139 non-users included at 12 months
Safety
Gastrointestinal and post-MBS adverse events · 6 and 12 months
- No increased risk of adverse events at either time point
Original publication
Real‐World Effectiveness and Safety of GLP ‐1 Receptor Agonists Among Patients With Weight Recurrence After Bariatric Surgery. Obesity (Silver Spring). Published 25 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →